Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 17/20 | 0.70 |
| ▸ | SLC22A12 | Q96S37 | 6/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20915664 | 0.86 | XDH (0.67) | XDHSLC22A12 | |
| SCHEMBL22364252 | 0.81 | XDH (0.67) | XDHSLC22A12 | |
| SCHEMBL10733888 | 0.79 | XDH (0.65) | XDHSLC22A12 | |
| SCHEMBL20179427 | 0.73 | XDH (0.61) | XDHSLC22A12 | |
| SCHEMBL20179455 | 0.72 | XDH (0.60) | XDHSLC22A12 | |
| SCHEMBL20915726 | 0.69 | XDH (0.67) | XDHSLC22A12 | |
| SCHEMBL20915704 | 0.65 | XDH (0.69) | XDHSLC22A12 | |
| SCHEMBL20915847 | 0.65 | XDH (0.69) | XDHSLC22A12 | |
| SCHEMBL20915739 | 0.65 | XDH (0.69) | XDHSLC22A12 | |
| SCHEMBL22353091 | 0.65 | XDH (0.72) | XDHSLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024900-A1 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC (US) | 2022-01-27 | — | — | US | disclosed |
| US-11168075-B2 | Compounds and their use for reducing uric acid levels | ACQUIST LLC (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210236495-A1 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC (US) | 2021-08-05 | — | — | US | disclosed |
| US-11020397-B2 | Compounds and their use for reducing uric acid levels | ACQUIST LLC (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200347034-A1 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC (US) | 2020-11-05 | — | — | US | disclosed |
| US-10759784-B2 | Compounds and their use for reducing uric acid levels | ACQUIST LLC (US) | 2020-09-01 | — | — | US | disclosed |
| US-20200268757-A1 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC (US) | 2020-08-27 | — | — | US | disclosed |
| US-20200197393-A9 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC | 2020-06-25 | — | — | US | disclosed |
| US-10688095-B2 | Compounds and their use for reducing uric acid levels | ACQUIST LLC (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190117654-A1 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC (US) | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347034-A1 | Compounds and Their Use for Reducing Uric Acid Levels | XDH, OAT, PON1 | XDH 1/4885SLC22A12 327/4885ROCK1 4450/4885 |
| US-20220024900-A1 | Compounds and Their Use for Reducing Uric Acid Levels | XDH, OAT, PON1 | XDH 1/4885SLC22A12 327/4885ROCK1 4450/4885 |
| US-11168075-B2 | Compounds and their use for reducing uric acid levels | XDH, OAT, PON1 | XDH 1/4885SLC22A12 327/4885ROCK1 4450/4885 |
| US-10688095-B2 | Compounds and their use for reducing uric acid levels | XDH, OAT, UGT2B7 | XDH 1/4885SLC22A12 437/4885ROCK1 4692/4885 |
| US-20210236495-A1 | Compounds and Their Use for Reducing Uric Acid Levels | XDH, OAT, URB2 | XDH 1/4885SLC22A12 372/4885ROCK1 4587/4885 |
| US-20200268757-A1 | Compounds and Their Use for Reducing Uric Acid Levels | XDH, OAT, URB2 | XDH 1/4885SLC22A12 372/4885ROCK1 4587/4885 |
| US-10759784-B2 | Compounds and their use for reducing uric acid levels | XDH, OAT, PON1 | XDH 1/4885SLC22A12 327/4885ROCK1 4450/4885 |
| US-11020397-B2 | Compounds and their use for reducing uric acid levels | XDH, OAT, UGT2B7 | XDH 1/4885SLC22A12 437/4885ROCK1 4692/4885 |
| US-20200197393-A9 | Compounds and Their Use for Reducing Uric Acid Levels | XDH, OAT, URB2 | XDH 1/4885SLC22A12 372/4885ROCK1 4587/4885 |
| US-20190117654-A1 | Compounds and Their Use for Reducing Uric Acid Levels | XDH, OAT, URB2 | XDH 1/4885SLC22A12 372/4885ROCK1 4587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.